Obese associated type 2 diabetes

Indication for Rimonabant

Population group: Suitable for both men and women, only adults (18 years old or older)

As an adjunct to diet and exercise for the treatment of obese patients (BMI ≥30 kg/m²), or overweight patients (BMI >27 kg/m²) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia.

For this indication, competent medicine agencies globally authorize below treatments:

20 mg once daily

Route of admnistration


Defined daily dose

20 - 20 mg

Dosage regimen

From 20 To 20 mg once every day

Detailed description

In adults, the recommended dosage is one 20 mg daily to be taken in the morning before breakfast.

The treatment should be introduced with a mildly reduced calorie diet.

The safety and efficacy of rimonabant have not been evaluated beyond 2 years.

Dosage considerations

It should be taken in the morning before breakfast.

Active ingredient

Rimonabant is a selective cannabinoid-1 receptor (CB1) antagonist that inhibits the pharmacological effects of cannabinoid agonists in vitro and in vivo. The endocannabinoid system is a physiological system present in brain and peripheral tissues (including adipocytes) that affects energy balance, glucose and lipid metabolism and body weight, and in neurons of the mesolimbic system modulates the intake of highly palatable, sweet or fatty foods.

Read more about Rimonabant

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner